NCOA3 and lung carcinoma: Knockdown of SRC‐3 in lung cancers not only reduces cell growth and proliferation of non–small cell lung cancer cell lines but also potentiates the effects of gefitinib in EGFR tyrosine kinase inhibitor‐resistant cells 14.